You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.